Cargando…

Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections

Dalbavancin is a lipoglycopeptide antibiotic recently approved by the United States Food and Drug Administration (FDA) for acute bacterial skin and skin structure infections (ABSSSIs). It is active against gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), and min...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Jordan R., Roberts, Karrine D., Rybak, Michael J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575294/ https://www.ncbi.nlm.nih.gov/pubmed/26341488 http://dx.doi.org/10.1007/s40121-015-0077-7

Ejemplares similares

Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections
por: Brade, Karrine D., et al.
Publicado: (2016)

Telavancin: A novel lipoglycopeptide antibiotic
por: Damodaran, S. E., et al.
Publicado: (2011)

200. Real-World Experience with Dalbavancin for Complicated Gram-Positive Infections: A Multicenter Evaluation
por: Alosaimy, Sara, et al.
Publicado: (2019)

617. Long Acting Lipoglycopeptide Use in Veterans for Serious Gram-Positive Infections in the COVID Era
por: Saldana, Carlos S, et al.
Publicado: (2021)

Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections
por: Bork, Jacqueline T., et al.
Publicado: (2019)

1553. Efficacy and Safety of Dalbavancin and Oritavancin in the Treatment of Gram-Positive Infections
por: Brown, Vanessa, et al.
Publicado: (2020)

687. Use of Dalbavancin in Gram-positive Infective Endocarditis: Review of Current Literature
por: Fazili, Tasaduq, et al.
Publicado: (2021)

Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis
por: Kussmann, Manuel, et al.
Publicado: (2018)

Staphylococcus aureus is able to generate resistance to novel lipoglycopeptide antibiotic gausemycin A
por: Poshvina, Darya V., et al.
Publicado: (2022)

Specific Inhibition of VanZ-Mediated Resistance to Lipoglycopeptide Antibiotics
por: Sur, Vishma Pratap, et al.
Publicado: (2021)

Biofilm-Related Infections in Gram-Positive Bacteria and the Potential Role of the Long-Acting Agent Dalbavancin
por: Oliva, Alessandra, et al.
Publicado: (2021)

Successful use of dalbavancin in the treatment of gram positive blood stream infections: a case series
por: Evins, Connor, et al.
Publicado: (2022)

Long-term Dalbavancin for Suppression of Gram-Positive Chronic Left Ventricular Assist Device Infections
por: Rowe, Sarah, et al.
Publicado: (2023)

Long-Acting Lipoglycopeptides for Gram-Positive Bacteremia at the End of Life to Facilitate Hospice Care: A Report of 3 Cases
por: Datta, Rupak, et al.
Publicado: (2018)

Long-Acting Lipoglycopeptides: “Lineless Antibiotics” for Serious Infections in Persons Who Use Drugs
por: Morrisette, Taylor, et al.
Publicado: (2019)

DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2019)

Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections
por: Poliseno, Mariacristina, et al.
Publicado: (2021)

1081. Antimicrobial Activity of Dalbavancin Tested Against Gram-Positive Organisms Isolated From Patients With Infective Endocarditis in United States and European Medical Centers
por: Sader, Helio S, et al.
Publicado: (2018)

238. Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients with Bone and Joint Infections from the United States (US) and Europe (2016-2020): Results from the International Dalbavancin Evaluation of Activity (IDEA) Program
por: Sader, Helio S, et al.
Publicado: (2021)

Engineered biosynthesis of enduracidin lipoglycopeptide antibiotics using the ramoplanin mannosyltransferase Ram29
por: Wu, Ming-Cheng, et al.
Publicado: (2015)

Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018–2020)
por: Sader, Helio S., et al.
Publicado: (2022)

217. Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients Hospitalized with Bacteremia in United States and European Medical Centers: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program (2018-202)
por: Sader, Helio S, et al.
Publicado: (2021)

Two Novel Semisynthetic Lipoglycopeptides Active against Staphylococcus aureus Biofilms and Cells in Late Stationary Growth Phase
por: Vimberg, Vladimir, et al.
Publicado: (2021)

VanZ Reduces the Binding of Lipoglycopeptide Antibiotics to Staphylococcus aureus and Streptococcus pneumoniae Cells
por: Vimberg, Vladimir, et al.
Publicado: (2020)

Comparative Analysis of Dalbavancin versus Other Antimicrobial Options for Gram-Positive Cocci Infections: Effectiveness, Hospital Stay and Mortality
por: de Pablo-Miró, Mar, et al.
Publicado: (2021)

Current and novel antibiotics against resistant Gram-positive bacteria
por: Perez, Federico, et al.
Publicado: (2008)

Tedizolid Phosphate: a Next-Generation Oxazolidinone
por: Rybak, Jeffrey M., et al.
Publicado: (2015)

Antimicrobial Activity of Dalbavancin and Comparator Agents Tested against Gram-Positive Clinical Isolates Causing Bone and Joint Infections in United States (US) Medical Centers (2011–2016)
por: Sader, Helio S, et al.
Publicado: (2017)

Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection
por: Lange, Anna, et al.
Publicado: (2023)

Current and future options for treating complicated skin and soft tissue infections: focus on fluoroquinolones and long-acting lipoglycopeptide antibiotics
por: Eckmann, Christian, et al.
Publicado: (2021)

Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens
por: Beiras-Fernandez, Andres, et al.
Publicado: (2010)

Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety
por: Ruiz-Sancho, Andrés, et al.
Publicado: (2023)

Dalbavancin
por: Barberán, José, et al.
Publicado: (2021)

Comparative In Vitro Activity of New Lipoglycopeptides and Vancomycin Against Ocular Staphylococci and Their Toxicity on the Human Corneal Epithelium
por: André, Camille, et al.
Publicado: (2023)

Dalbavancin: a novel antimicrobial
por: Chen, A Y, et al.
Publicado: (2007)

Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections
por: Jafari Saraf, Lida, et al.
Publicado: (2011)

Impact of the new membrane-targeting lipoglycopeptide antibiotic MCC5145 on the treatment of bacteremic pneumococcal pneumonia in mice
por: Ogunniyi, Abiodun D., et al.
Publicado: (2023)

The Combined Use of Gentamicin and Silver Nitrate in Bone Cement for a Synergistic and Extended Antibiotic Action against Gram-Positive and Gram-Negative Bacteria
por: Jackson, John, et al.
Publicado: (2021)

Synergistic effect of clinically used antibiotics and peptide antibiotics against Gram-positive and Gram-negative bacteria
por: ZHOU, YULING, et al.
Publicado: (2013)

Mechanisms of Antibiotic Resistance in Important Gram-Positive and Gram-Negative Pathogens and Novel Antibiotic Solutions
por: Kakoullis, Loukas, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ni23qgu5gjm2i1f8kudbfrpv8g